Sanofi, Evotec collaborate to Discover and Develop Novel Diabetes Therapies

11-Aug-2015 - Germany

Sanofi announced that it has entered strategic research collaboration with Evotecto develop beta cell-modulating diabetes treatments, which may reduce or eliminate the need for insulin injections.Beta cells play a key role in the pathogenesis of diabetes, a condition which currently affects 387 million patients worldwide.

The new research collaboration will focus on developing a beta cell replacement therapy based on functional human beta cells derived from human stem cells. The companies will also use human beta cells for high-throughput drug screening to identify beta cell active small molecules or biologics.

Under this agreement, Evotec will be entitled to receive development, regulatory and commercial milestone payments, which could total more than €300 million, and royalties on net sales.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance